Estrategias terapéuticas futuras para la preeclampsia basadas en la reducción del estrés oxidativo

Abstract

Background: preeclampsia (PE) is a condition that occurs after the 20th week of gestation, with hypertension and proteinuria, with a global prevalence of 4.6%.

Objective: to describe future therapeutic strategies for preeclampsia based on the reduction of oxidative stress.

Methodology: a narrative literature review was performed, including 22 articles collected from different databases such as Medline, Lilacs, TripDataBase, Cochrane Library, Epistemonikos.

Results: antioxidants and anti-inflammatory compounds offer promise in PE but need validation in clinical trials. Personalization, risks and benefits, mechanisms, interactions and side effects require attention. N-acetylcysteine significantly reduces malondialdehyde (MDA), IL-8 and homocysteine levels in patients with preeclampsia. However, it has no significant effect on CRP, TNF-α and IL-6 levels. As for aspirin, a positive effect on the prevention of preeclampsia is observed, especially when administered in low doses. Pravastatin reduces the incidence of preeclampsia by 61%. Combined therapy of Danshen and magnesium sulfate improves blood pressure, urinary protein, TNF-α levels, oxidative stress and therapeutic efficacy in severe preeclampsia.

Conclusions: these findings suggest several promising interventions in preeclampsia, but more research is needed.